In particular, we explored whether targeted inhibition of the mTOR/Akt axis could enhance NET-1 expression through downregulation of p-AktS473 using the dual mTOR complex 1 and 2 (mTORC1/2) inhibitor AZD2014 in MYCN amplified NB models in vitro and in vivo. The gene discussed is MYCN; the disease is neuroblastoma.